217 related articles for article (PubMed ID: 12745414)
1. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy.
Miguez-Burbano MJ; Burbano X; Ashkin D; Pitchenik A; Allan R; Pineda L; Rodriguez N; Shor-Posner G
Addict Biol; 2003 Mar; 8(1):39-43. PubMed ID: 12745414
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease.
Miguez-Burbano MJ; Ashkin D; Rodriguez A; Duncan R; Pitchenik A; Quintero N; Flores M; Shor-Posner G
Int J Infect Dis; 2005 Jul; 9(4):208-17. PubMed ID: 15916913
[TBL] [Abstract][Full Text] [Related]
3. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
4. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
5. The association between cigarette smoking and selected HIV-related medical conditions.
Conley LJ; Bush TJ; Buchbinder SP; Penley KA; Judson FN; Holmberg SD
AIDS; 1996 Sep; 10(10):1121-6. PubMed ID: 8874629
[TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
7. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
[TBL] [Abstract][Full Text] [Related]
8. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
9. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
10. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens.
Atzori C; Clerici M; Trabattoni D; Fantoni G; Valerio A; Tronconi E; Cargnel A
J Antimicrob Chemother; 2003 Aug; 52(2):276-81. PubMed ID: 12837736
[TBL] [Abstract][Full Text] [Related]
11. HIV and the lung.
Wallace JM
Curr Opin Pulm Med; 1998 May; 4(3):135-41. PubMed ID: 9675515
[TBL] [Abstract][Full Text] [Related]
12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
13. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
14. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis-associated organizing pneumonia as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected individual with a normal CD4+ T-cell count following antiretroviral therapy.
Mori S; Polatino S; Estrada-Y-Martin RM
Int J STD AIDS; 2009 Sep; 20(9):662-5. PubMed ID: 19710347
[TBL] [Abstract][Full Text] [Related]
16. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
[TBL] [Abstract][Full Text] [Related]
17. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
Breen RA; Miller RF; Gorsuch T; Smith CJ; Ainsworth J; Ballinger J; Swaden L; Cropley I; Johnson MA; Lipman MC
J Infect Dis; 2006 May; 193(10):1437-40. PubMed ID: 16619192
[TBL] [Abstract][Full Text] [Related]
18. Oral complication risks after invasive and non-invasive dental procedures in HIV-positive patients.
Campo J; Cano J; del Romero J; Hernando V; Rodríguez C; Bascones A
Oral Dis; 2007 Jan; 13(1):110-6. PubMed ID: 17241440
[TBL] [Abstract][Full Text] [Related]
19. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
